The Current Ratio as of September 2024 (TTM) for Pyxis Oncology, Inc. (PYXS) is 9.53

According to Pyxis Oncology, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 9.53. This represents a change of 21.15% compared to the average of 7.87 of the last 4 quarters.

Pyxis Oncology, Inc. (PYXS) Historical Current Ratio (quarterly & annually)

How has PYXS Current Ratio performed in the past?

The mean historical Current Ratio of Pyxis Oncology, Inc. over the last ten years is 10.94. The current 9.53 Current Ratio has changed 8.61% with respect to the historical average. Over the past ten years (40 quarters), PYXS's Current Ratio was at its highest in in the June 2021 quarter at 16.99. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Pyxis Oncology, Inc. (PYXS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Pyxis Oncology, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Pyxis Oncology, Inc. (PYXS) Average Current Ratio

How has PYXS Current Ratio performed in the past?

The current Current Ratio of Pyxis Oncology, Inc. (PYXS) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Pyxis Oncology, Inc. (PYXS) Current Ratio vs. Peers

How is PYXS’s Current Ratio compared to its peers?

Pyxis Oncology, Inc.’s Current Ratio is less than Zura Bio Limited (12.57), greater than eFFECTOR Therapeutics, Inc. (1.03), greater than Altamira Therapeutics Ltd. (1.38), less than Elevation Oncology, Inc. (41.10), greater than Mereo BioPharma Group plc (6.07), greater than PDS Biotechnology Corporation (3.84), greater than X4 Pharmaceuticals, Inc. (6.07), greater than Corvus Pharmaceuticals, Inc. (3.62), less than Terns Pharmaceuticals, Inc. (21.02), greater than ZyVersa Therapeutics, Inc. (0.06), greater than Ocean Biomedical, Inc. (0.03), less than Icosavax, Inc. (18.06), less than Inozyme Pharma, Inc. (9.84), greater than HOOKIPA Pharma Inc. (3.86),

Build a custom stock screener for Pyxis Oncology, Inc. (PYXS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pyxis Oncology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Pyxis Oncology, Inc. (PYXS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Pyxis Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.